Racism and health. Challenge to racism must continue

Citation for published version:

Digital Object Identifier (DOI):
10.1136/bmj.326.7394.880

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
British Medical Journal (BMJ)

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Racism and health

Challenge to racism must continue

Editor—As McKenzie highlights in his editorial, the emphasis to date has been on the role of racism in recruitment and career development.1 This must continue despite initiatives and legislation such as the recent Race Relations Amendment Act, as racism still exists in the NHS.2 We need to continue to challenge racism not only from our colleagues but also from our patients—zero tolerance is needed.

The importance of racism on health and health care will not diminish owing to increasing migration to the United Kingdom particularly from east European countries. The often hostile reception of the public, media, and some politicians reinforces the negative attitudes that prevail, and these may manifest through acute and chronic stress to the detriment of the individual. Research on evaluating the mechanism for racism and health outcomes is in early infancy; most studies are being conducted in the United States. We agree with McKenzie that further funding is needed in this area.

The biological models alluded to seem plausible, but before investigating these further substantial research needs to be done first to define, measure, and validate “racism” as an epidemiological variable. Then we need studies to disentangle the effect of racism on health. Urgency and opportunity exist to initiate a national ethnic cohort study within the planned UK Biobank study (www.ukbiobank.ac.uk) to include examination of the effect of racism on health outcomes.

Paramjit S Gill clinical senior lecturer Department of Primary Care and General Practice, University of Birmingham Medical School, Birmingham B15 2TT ps.gill@bham.ac.uk
Raj S Bhopal Aruze and John Usher professor of public health Department of Community Health Sciences, University of Edinburgh Medical School, Edinburgh EH8 9AG

Competing interests: None declared.

Author’s reply

Editor—I agree with Gill and Bhopal that the challenge to racism must continue, and there should be zero tolerance. Racism is complex, and so the response will need to be wide based.

Research has been conducted in the United States and United Kingdom on the nature of racism. There will always be a need to refine measures, but survey tools and instruments are available, supported by a robust literature, that are being used in the United Kingdom.

I support the need for a national ethnic minority cohort study to try to disentangle the effects of racism on health. This should be separate from Biobank. Biobank samples people aged over 45. It will not be able to address the effect of racism on younger people and pregnant women. It will not address ecological effects. It will not address the changing demographics of areas or populations that may influence the impact of racism on health.

Some may be uncomfortable with the scientific paradigm of Biobank and may call for consultation with black and ethnic minority groups. Oversampling of people of black and ethnic minority groups within Biobank would be useful. If the samples simply reflected the percentage of the ethnic minority populations over 45 in the United Kingdom the study may not have sufficient power for meaningful subgroup analysis. It could be argued that the research would not have delivered equity because it is not as useful to minority groups. It could be argued that it is therefore discriminatory. I am unsure whether this could lead to a challenge under the Race Relations Amendment Act.

However, oversampling in Biobank should not be confused with a proper research effort that addresses the issue of racism and health. Biobank may be useful, but it is too limited to offer the answers required.

Kwame McKenzie senior lecturer in transcultural psychiatry Department of Psychiatry and Behavioural Sciences, Royal Free and University College Medical School, London NW3 2PF kw.mckenzie@rfc.ac.uk

Competing interests: None declared.

Australia’s Aboriginals suffer disproportionate burden of ill health

Editor—McKenzie has highlighted the association between racism, morbidity and mortality.1 I respond as an epidemiologist for Aboriginal health in central Australia.

About 20 000 Aboriginal people live in central Australia, most of them in small communities scattered across the vast desert area. Aboriginal Australians have a disproportionate burden of ill health compared with their non-Aboriginal counterparts. Their life expectancy is about 20 years lower, and 58% of Aboriginals die before the age of 55.2 Their morbidity load is far greater than that of non-Aboriginals, and the bulk of morbidity is due to chronic diseases such as diabetes, heart disease, and chronic obstructive airways disease. From birth weight to life expectancy, disparities in health indicators between the two populations are glaring.

Much of the research work in the past has been directed at socioeconomic status, cultural factors, and position in the social hierarchy. Not much attention has been given to racism and its effects on health status. McKenzie’s editorial implies that racism may be aetiologically important in the development of illness.3 Overt or implicit racial discrimination is recognised to be the underlying cause for poor health status.4 Although research based evidence is scant to show that racism being the underlying cause for health inequalities in central Australia, there are some setbacks in the system that may be aggravating the disparity:

● Inappropriate responses from health services
● Lack of coordination among various categories of healthcare staff
● Absence of mechanisms for evaluating the effectiveness of services
● Lack of a public health and epidemiological approach
● High turnover of healthcare staff.

These factors may well be the consequences of intrinsic racism in the system. The disturbing health inequalities between Aboriginal and non-Aboriginal population are acknowledged time and again, but no appropriate action seems to be in place to address these problems and reduce the inequity gap. Requisite skills and knowledge to rectify these problems may be lacking among key managerial staff. I hope the above factors are given serious consideration while planning services that would in turn generate effective solutions.

Ruby Kaul epidemiologist Department of Health and Community Services, PO Box 721, Alice Springs, Northern Territory 0871, Australia

Competing interests: None declared.

Spirituality and clinical care

**Placebo or not—we may never know**

**Editor**—I agree with Culliford that knowing your patients better makes for a better therapeutic relationship.1 Often—for example, in terminal care or when physical measures do not have an impact on any disease—being able to relate in “wider” terms can increase the potential for healing. But I disagree with Culliford on the question of methodology.

Most religions and other arenas of spirituality use ritualised gestures, incantations, prayers, symbolism, and rites. Unless you believe that these processes have effects through a perceived extracorporeal being, power, or energy, the effect is presumed to come from within patients themselves. But the placebo effect is inherently based on its own camouflage. Once you know you’re taking placebo then the magic is lost.

The entire effect is dependent on your “faith” in the procedure. Although I might deliberately use the placebo effect in my pharmaceutical treatment of patients, is it not an unethical deceit for me to portray a facade of spirituality for their benefit when I don’t believe it myself? If that is true then what is Culliford suggesting? Might it be that my deficiencies as a non-believer translate into deficiencies as a doctor? Perhaps I don’t really want an answer to that.

**Daniel R Netherton**

Senior house officer, palliative medicine
Holme Tower, Marie Curie Centre, Penarth,
South Glamorgan CF64 3VR
danielr.netherton@hotmail.com

**Competing interests:** DRN is a practising atheist.


**Spiritual care based primarily on happiness is dangerous**

**Editor**—Culliford’s editorial reflects a resurgent interest in spiritual aspects of healing through discontent with a purely materialistic world view.1 Our culture does not believe in a pure scientific reductionist model that says we are made solely of a materialistic world view.1 Our experience tells us there is a greater depth to life, and I welcome Culliford’s recognition of this as central in healthcare provision. However, for a spiritual awareness and treatment based primarily on outcomes of happiness and wellbeing is dangerous. Leading patients to believe that spirituality brings happiness may cause upset through disappointment or more seriously propound disregard for spiritual truth—“It doesn’t matter what you believe as long as it makes you happy.” Of far greater importance is “Is it true or not?”

Consider Christianity as an example. The experience of many is that faith brings a deep joy that surpasses day to day happiness and upset. However, Christianity does not always bring happiness. Christ claimed he was God’s son and was crucified for it. Many who followed him since have been martyred for their beliefs, and countless more suffer daily persecution for being called “Christian.” Living out the Christian faith in itself hard work. Therefore it matters whether this faith is based on truth.

The spiritual side of clinical care is important. We should be careful, however, to avoid misleading spiritual platitudes that bring happiness at the expense of truth.

**Matt J Hawker**

Senior house officer, phlebology
Worcestershire Acute Hospitals NHS Trust,
Worcester WR5 1BD
mehardy@freerouteame.co.uk

**Competing interests:** MH is a Christian.


**Spirituality is not everyone’s cup of tea for treating addiction**

**Editor**—Culliford’s editorial about spirituality in medicine raises some important issues. In alcohol and drug treatment the spiritual dimension can play a part in recovery. The 12 step model developed by Alcoholics Anonymous has several important therapeutic elements, one of which is promoting the development of spirituality, and the large Project MATCH study of drinking outcomes found 12 step facilitation to be as effective as other forms of psychological treatment.

We recently conducted a questionnaire survey of 60 people attending Narcotics Anonymous groups in the West Midlands. We asked the attenders to rate their level of group attendance and participation, their belief in a higher power, and the amount of time that they devoted to any form of spiritual practice. The results showed that 90% of the participants had a belief in a power greater than themselves, and on average 50% allowed time for spiritual practices at least once daily. Linear regression analysis showed that spiritual practices, along with attendance and engagement with the self help groups, were significant predictors of abstinence in this group of substance misusers.

The finding that participants allow themselves some time to engage in spiritual activities every few days is consistent with the work of Finney and Maloney, who found that taking meditation to be an effective means of preventing relapse in this group.2 It also links to Geiser’s work, which shows that spiritual practices combined with psychosocial treatment are effective aids to misusers in reducing their drug use,3 as well as to other work that indicates that prayer and meditation positively influences coping.

We believe, however, that the spiritual dimension is potentially a double edged sword for engagement in self-help groups. Although Alcoholics and Narcotics Anonymous have over two million members worldwide, few of the people whom we treat use this free and readily available form of long term help. Our clinical experience implies that the perceived “religious” or spiritual element of the process is a strong reason to stop attending self help groups of these organisations, particularly in the early stages.

**Ed Day**

Consultant psychiatrist e.day@blueyonder.co.uk

**Simon Wilkes**

Consultant psychologist
Alex Copello Consulting psychologist Addictive Behaviours Centre, Birmingham B4 6XQ

**Competing interests:** None declared.


**National service framework for diabetes leaves questions open**

**Editor**—The much delayed national service framework for diabetes has major implications for primary and secondary care services in England. Many of its proposals are to be welcomed, but some of them are vague, with little indication of how they can be implemented.

The most serious problem is the absence of identified resources to allow improvements in diabetes care to be implemented effectively. We are informed that there will be some funding for retinal cameras, but no indication is given about how the revenue consequences of major screening programmes will be addressed. We are told that funds for the national service framework will be provided to primary care trusts in the baseline allocation for general medical services, but there is no guarantee that these will be ringfenced. In many areas new monies seem to have already been swallowed up by historical debts.

Much of the focus of the national service framework is on primary care, but diabetes expertise is lacking in many practices.2 Developing the necessary skills in primary care will need an educational programme, which will depend on local specialist diabetes services. The Association of British Clinical Diabetologists has already shown deficiencies and lack of resources (especially in numbers of consultants, specialist nurses, dietitians, and podiatrists) in many specialist centres, so it is hard to see how the necessary support can be provided.

Already there are major medical recruitment problems, with trusts being unable to attract suitable candidates for posts such as consultant diabetologists. Without adequate specialist diabetes services there is a real risk of substantial delays for diabetes leaves questions open...
diabetes care in many districts. The resource and staffing consequences of the national service framework need to be addressed urgently, otherwise its impact will be minimal, care overall will not improve, and the morbidity and mortality in the diabetic population will not be reduced.

Richard H Greenwood chairman richard.greenwood@mmuh.nhs.uk

K M Shaw honorary secretary

P Winocour honorary secretary

Association of British Clinical Diabetologists, London WIP 1HQ

Competing interests: None declared.

Using risk tables to assess cardiovascular risk in type 2 diabetes has drawbacks

Entror—Hall et al describe the use of primary prevention risk tables in type 2 diabetes.1 We agree that targeting cardiovascular risk in diabetes is a priority, but their proposals imply an overreliance on risk scores as the sole determinant of cardiovascular risk assessment in diabetes. This approach might lead to withholding treatment in some people whose risk is underestimated by risk scores.

Unfortunately, the decision at what level of cardiovascular risk to start lipid lowering treatment in diabetes is not straightforward. The authors’ oversimplistic approach, although convenient, is unsound and flies in the face of epidemiological evidence which suggests that type 2 diabetes should be regarded as a disease group for secondary rather than primary prevention.2 Using the Framingham equation to evaluate cardiovascular risk in diabetes entails caveats. These include a low baseline prevalence of diabetes in the Framingham cohort and the omission from the equation of triglyceride concentration, an important determinant of cardiovascular risk in type 2 diabetes.3 The low prevalence of diabetes in the cohort leads to wide confidence intervals in the predicted risk. Thus, in a diabetic man with average risk factors, the upper 95% confidence interval crosses the 15%, 10 year threshold from the age of 40 onwards.4

People with risk scores below a chosen cut-off point may therefore have a higher true risk. The proposals by Hall et al would lead to a rigid prescribing protocol whereby all patients with scores above a threshold (for example, 15%) would receive treatment, whereas those below would not. Furthermore, an overemphasis on the risk score might be at the expense of ignoring other key factors not represented by the Framingham risk equation, such as ethnic group, family history, microalbuminuria, and triglyceride concentration.

Jamie Smith special registrar jamie.smith@virgin.net

Roger Corrall consultant physician Department of Diabetes and Endocrinology, Bristol Royal Infirmary, Bristol BS2 8HW

Competing interests: None declared.

Letters

Cardiovascular risk scores and prescribing in diabetes

Failing to bark and barking

EDITOR—Le Fanu’s Sherlock Holmes style case of the missing data and dog that failed to bark had amusing elements but also misunderstandings, errors, and accusations of concealment, implying had faith.

1 Evans JM, Wong J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002;325:95-42.


Authors’ reply

Editor—The purpose of our paper was to identify whether there was clinical value in using cardiovascular risk scores. We wanted to identify whether having an integrated single score of macrovascular cardiovascular risk highlights to clinicians that a clinical issue needs addressing, which influences their prescribing habits. Our paper indicates that this is the case and that in the setting of a busy clinic having to assess a multitude of individual risk factors may result in cardiovascular risk being overlooked. Having established that an integrated score is useful to practising clinicians, the next challenge is to identify an appropriate risk score to use.

Smith and Corrall correctly indicate that the New Zealand risk score, and others based on Framingham, all underestimate the cardiovascular risk in diabetes, although data from Tayside indicate that this is probably not to the extent suggested by Haffner et al.1 Also, the level of risk chosen to start treatment is an arbitrary cut-off point which can be adjusted—for example, to 15% from 20%—if thought desirable. The real answer is to define the epidemiology of cardiovascular risk in diabetes more accurately so that more accurate tables can be developed.

Graham P Leese consultant in diabetes graham.leese@nuh.nhs.uk

Lesley Hall medical student

Roland Jung consultant Ninewells Hospital, Dundee DD10 8Y

Competing interests: None declared.

1 Evans JM, Wong J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002;325:95-42.


229-34.


Competing interests

Consent was not obtained

Editor—So, the editor of the BMJ is happy to coauthor research involving undeclared deception of subjects and publish it in his journal.1 Three hundred readers were unwitting dupes. They took part without being informed what the real object of the exercise was, no informed consent here, at least not by the standard of being willing to show the subject the research protocol. This sort of research violates Kant’s categorical imperative—act as if this were a universal principle. It seeks payment in a coin that it debases for others.2 BMJ readers should be warned: next time a researcher contacts you for an opinion, it is probably a hoax.

What is ironic about the paper is that the results have meaning only if the respondents were more honest than the authors. My warning to researchers is as follows: if you deceive your subjects what right have you to expect they will not do the same to you?3

Stephen J Senn professor of pharmaceutical and health statistics University College London, London WC1E 6BT stephens@public-health.ucl.ac.uk

Competing interests: SJS is a consultant to the pharmaceutical industry and an academic. His career is therefore furthered by publication.


Problem is greater than editorial indicates

Editor—The BMJ should be congratulated for its efforts to avoid bias in the reporting of scientific work.4 Asking editors and authors explicitly to state competing interests reduces the likelihood of bias. As Smith rightly says, however, we still have some way to go to the fully transparent world. Much of the discussion of conflict of interest may leave the impression that the problem lies in commercial sponsorship, in particular from the pharmaceutical and tobacco industries. The problem may be more widespread, however. Could researchers in a public health institute be influenced by political pressures when the institute is financed directly by the health ministry? Will the pressure become stronger when the research institute is placed within the ministry? Can researchers who receive honoraria for advising government and courts on tobacco issues be influenced by the fees they receive? If researchers can be influenced by commercial sponsorship, and the evidence here is convincing, why should researchers be immune to influence from other sponsors? Nevertheless, it is not unusual that research financed by government and other non-commercial sources is presented without warning the reader that there is a potential conflict of interest.

My point is not that bias from commercial sponsorship should be belittled but rather to emphasise that the problem is greater than Smith’s editorial may indicate.

Policies to avoid bias in the conduct and reporting of research should be guided by scientific principles, not by moralism or prejudice.5

Ivar S Kristiansen senior researcher Institute of Public Health, University of Southern Denmark, DK-5000 Odense, Denmark ivarski@clin.dtu.dk

Competing interests: ISK has received salary and honoraria from several public institutions and honoraria from several pharmaceutical firms. He has not received honoraria from the tobacco industry.

1 Smith R. Making progress with competing interests. BMJ 2002;325:1375-6. (14 December.)

It’s my journal, and I’ll write if I want to

Editor—Richard and colleagues just walked Through the door Like a king with his court. He says he’s got a great idea And surely to publish they ought.

Sorry, my muse left on holiday after that. Please feel free to add some more verses. Like other respondents, I applaud the BMJ’s crusade to enlighten readers about the issues of conflicting interests.6 The paper by Chaudhry et al should surely have been submitted to another journal, or if not someone else should have it.7 The BMJ’s peer journals are not the BMJ itself.

Could we be informed as to how long the paper was out at the reviewers and how quickly it got accepted in its final version? It was published within six weeks of acceptance. That’s nice. I have had work published in the BMJ, on one occasion after the manuscript (and I am quoting directly from the correspondence at the time) “lay in the top drawer” of a staff statistician’s desk for six months. I doubt that would ever happen to an editor’s paper.

These are small points but if the BMJ’s crusade is to be credible and successful, inhouse guidelines about staff submissions should be torn up and replaced by a rule that BMJ related work is only submitted elsewhere.

Jonathan O B Hourihan senior lecturer, infections, inflammation, and repair Mailpoint 218, Southampton University Hospitals NHS Trust, Southampton SO16 6YD j.hourihan@soton.ac.uk

Competing interests: None declared.

1 Smith R. Making progress with competing interests. BMJ 2002;325:1375-6. (14 December.)

Barriers to managing heart failure in primary care

Heart failure clinics provide crucial link between primary and secondary care

Editor—Fuat et al surveyed attitudes towards managing heart failure in general practice.1 Points of particular note included difficulties in assessing subtle early signs of heart failure, difficulties in interpreting echocardiography reports, and concerns about the number of drugs recommended for patients with heart failure. This study further strengthens the case for specialist heart failure clinics as outlined in the national service framework for coronary heart disease.2 Such clinics have a multidisciplinary team consisting of physicians (specialist and primary care), specialist nurses, and cardiac technicians, and these teams facilitate a coordinated approach to diagnosing, assessing, and managing heart failure. Objective evidence of cardiac dysfunction may be obtained and interpreted by a cardiologist, with the subsequent formulation of a treatment strategy.

We believe that this is preferable to open access echocardiography services, with the difficulties in interpretation highlighted by Fuat et al.3 Specialist dedicated nursing provides a crucial bridge between hospital and community care, allowing continued clinical assessment and appropriate titration of drug treatment, as well as continued patient education. Such nursing has been associated with a significant reduction in hospital readmission for heart failure.4 Widespread awareness of current treatment guidelines seems to be lacking in primary care; dedicated nursing services

Jonathan O B Hourihan

References

can be instrumental in implementing guidelines.

Heart failure is thought to invariably affect elderly people. This is simply not true. Clearly the disease becomes more prevalent with age, but diagnosis is delayed in many young patients with dilated cardiomyopathy because of this perception.

Heart failure has a high prevalence and is associated with a terrible prognosis, despite the availability of evidence based treatments. General practitioners are at the sharp end of an escalating problem, and specialist clinics provide invaluable support for the growing burden of chronic heart failure.

Russell C Davis consultant cardiologist
RC.Davis@bham.ac.uk

Gurbir Bhatia research fellow
Michael Sozin research fellow
Jane Stubley senior heart failure specialist nurse
Sandwell and West Birmingham NHS Trust, West Bromwich B71 4HH

Competing interests: None declared.

Previous study revealed other factors to be important in management

Enerton—Fuat et al describe an important problem in their article on diagnosing and managing heart failure in primary care. We investigated this same issue by semistructured interviews with individual general practitioners. This investigation undertaken in 1998 identified many themes that were common to Fuat et al’s study using focus groups of general practitioners. However, two important themes we identified are absent in this later study.

The first is that discussion of patients with “suspected heart failure” was very difficult, general practitioners more readily identifying with symptom based scenarios, such as managing breathless patients. The second theme was “therapeutic trials.” Most general practitioners described difficulties in distinguishing between chronic obstructive pulmonary disease and heart failure. Several general practitioners described using bronchodilators or diuretics to determine which could alleviate symptoms, arriving at a symptomatic rather than pathophysiological diagnosis.

The general practitioners we interviewed were aware of the benefits of angiotensin converting enzyme inhibitors, but symptom control seemed to be the focus of management in many cases. These additional factors, which featured highly in the thinking of some practitioners, should be taken account of in the design of any future interventions to improve the management of heart failure in primary care.

Mark F Lambert director of public health
Gateshead Primary Care Trust, Gateshead NE11 5QR
mark.lambert@gpht.nhs.uk

Ian S Watt professor of primary and community care
University of York, York Y010 5DD

Competing interests: None declared.


Congestion charging

Walking classes also need road space reallocation

EDITOR—We welcome Roberts’s editorial, making the health case for the London congestion charge,1 particularly as the revenue is required to be spent on transport. We agree that physically active transport such as walking and cycling is likely to increase. This must be monitored adequately, with attention given to changes in activity levels2 and broken down by sociodemographic groups, to assess the impacts on health and inequities.

Other potential effects of congestion charging include improvement in access for emergency vehicles. However, not all are positive: the impact of the policy will depend on which complementary measures are introduced at the same time.

Firstly, we disagree that less car travel will result in fewer crashes; this impact is difficult to predict.3 It depends whether journey times are shorter because of less time queuing at junctions or because of higher speeds. If traffic reduction is greater than was predicted, travel speeds may become substantially faster. While shorter journey times could reduce exposure to the risk of collisions, higher speeds could increase the risk by a greater amount.

Secondly, congestion charging alone could adversely affect equity: road space vacated by people who are deterred by the charge could be occupied by the wealthy, who are less price sensitive.4 Both effects can be effectively combated by simultaneously introducing measures to reallocate road space and giving priority to vulnerable groups: pedestrians (10-18 times the accident rate of car drivers per 2 km journey) and cyclists (13 times the accident rate of car drivers per 2 km journey), yet he thinks that increasing the size of both of these vulnerable groups by encouraging people to walk or cycle will decrease the number of accidents. Statistical nonsense.

It is generally agreed that the only pollutant to constitute a health hazard at current levels is a small particle emission. How can moving from clean petrol driven cars to dirty diesel buses (buses do not have to conform to any emission standards) help this?

Since there are only about 16 state schools within the congestion charge zone it is absurd to suggest it is going to make mothers happy to allow their children to walk to school throughout the country.

To compare Ken Livingstone to Edwin Chadwick is particularly absurd. Chadwick’s plans for sanitation were drawn up at the request of parliament and largely implemented without opposition. He is remembered for his controversial Poor Law Act of 1834, which confined the poor to institutions where families were separated and deliberately subjected to discomfort “to punish them for their indolence.” There may be a case for congestion charges but it is not on the grounds of improving health or safety. I cannot believe that this editorial was critically reviewed before publication.

Stanley Feldman professor
28 Moore Street, London SW3 2QW

Competing interests: None declared.

1 Roberts I. Congestion charging and the walking classes. BMJ 2003;326;345-6. (15 February)

Political polemics are masquerading as science

EDITOR—Roberts in his editorial on congestion charging is wrong in almost all of his assertions.1 The number of cars on the road in central London has remained stable over the past 30 years until it fell by 18% last year (Transport for London statistics). Slow journey times and congestion are due to more people working in central London and poor road management.

Roberts acknowledges that the vulnerable groups are pedestrians (10-18 times the accident rate of car drivers per 2 km journey) and cyclists (13 times the accident rate per 2 km journey), yet he thinks that increasing the size of both of these vulnerable groups by encouraging people to walk or cycle will decrease the number of accidents. Statistical nonsense.

It is generally agreed that the only pollutant to constitute a health hazard at current levels is a small particle emission. How can moving from clean petrol driven cars to dirty diesel buses (buses do not have to conform to any emission standards) help this?

Since there are only about 16 state schools within the congestion charge zone it is absurd to suggest it is going to make mothers happy to allow their children to walk to school throughout the country.

To compare Ken Livingstone to Edwin Chadwick is particularly absurd. Chadwick’s plans for sanitation were drawn up at the request of parliament and largely implemented without opposition. He is remembered for his controversial Poor Law Act of 1834, which confined the poor to institutions where families were separated and deliberately subjected to discomfort “to punish them for their indolence.” There may be a case for congestion charges but it is not on the grounds of improving health or safety. I cannot believe that this editorial was critically reviewed before publication.

Stanley Feldman professor
28 Moore Street, London SW3 2QW

Competing interests: None declared.

1 Roberts I. Congestion charging and the walking classes. BMJ 2003;326;345-6. (15 February)

Letters appearing here are an edited selection of rapid responses originally posted on bmj.com

We ask for all letters to the editor to be submitted as rapid responses via bmj.com

For advice see: bmj.com/agp/rapid-responses

bmj.com

884

BMJ VOLUME 326 19 APRIL 2003 bmj.com